Maria Grazia Rodriquenz

Dr. Maria Grazia Rodriquenz


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Maria Grazia RodriquenzMaria Grazia Rodriquenz
Maria Grazia Rodriquenz
giandomenico roviellogiandomenico roviello
giandomenico roviello
ADAlberto D'Angelo
Alberto D'Angelo
DLDaniele Lavacchi
Daniele Lavacchi
FRFranco Roviello
Franco Roviello
KPKarol Polom
Karol Polom
Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes— Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer’s subgroups and their relationship with novel immunotherapy.

21 September 2023 in International Journal of Surgery
Verified
Journal Article
Open access
FFFrancesca De Felice
Francesca De Felice
CCCarlo Guglielmo Cattaneo
Carlo Guglielmo Cattaneo
GPGianmario Edoardo Poto
Gianmario Edoardo Poto
CACarmine Antropoli
Carmine Antropoli
ABAntonio Brillantino
Antonio Brillantino
Luigi MaranoLuigi Marano
Luigi Marano
The ongoing global health challenge of cancer is driving the pursuit of innovative avenues for prevention, treatment, and enhanced outcomes. The convergence of nutrition and immune modulation, known as immunonutrition, is ready to act as a catalyst for transformative change in cancer research and therapy. Our study employs a bibliometric analysis to uncover the evolving trends within immunonutrition and cancer research across the past 25 years. Bibliometric data, including authors, journals, affiliations, and countries, were analyzed using the Bibliometrix R package. Clustering algorithms were applied to keywords to identify thematic areas and their evolution. A total of 489 documents were analyzed, showing an annual growth rate of 8.7%, with a collaboration index of 5.41, highlighting comprehensive multidisciplinary involvement within this landscape. Core authors demonstrated sustained productivity, while occasional authors indicated widespread interest. The Medical University of Warsaw led in institutional contributions. Country-wise, Italy, France, and the USA emerged as forerunners in fostering research productivity. Key journals like ʻClinical Nutritionʼ served as beacons, emphasizing the multidimensional nature of this topic. The analysis highlighted growing research output and several collaborations, indicating the importance of immunoenriched nutrition in cancer treatment. The interplay of core authors and diversified engagement harmoniously accentuates the cross-disciplinary nature of this burgeoning field. International collaboration facilitated knowledge exchange. Prominent documents shaped the field, emphasizing the significance of nutritional interventions. Thematic clusters revealed varied focuses, including pharmaconutrients, surgical approaches, inflammation, and specific cancers. The expanding research output suggests further development, particularly in exploring immunoenriched nutrition’s impact on cancer types and patient populations. The multidisciplinary nature and international collaborations enhance the field’s progress. Gaps in research underscore the need for original studies and personalized approaches. This study guides future research, informing evidence-based nutritional interventions and advancing cancer care practices.

15 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSara Stumpo
Sara Stumpo
MFMaria Giovanna Formelli
Maria Giovanna Formelli
IPIrene Persano
Irene Persano
EPElena Parlagreco
Elena Parlagreco
ELEleonora Lauricella
Eleonora Lauricella
GLGiuseppe Lamberti
Giuseppe Lamberti
Neuroendocrine carcinomas (NECs) are poorly differentiated and highly aggressive epithelial neuroendocrine neoplasms. The most common primary site is the lung, but they may arise in every organ. Approximately 37% of extrapulmonary NECs (EP-NECs) occur in the gastroenteropancreatic (GEP) tract, followed by the genitourinary (GU) system and gynecological tract. As a result of their rarity, there is scant evidence to guide treatment recommendations, and a multidisciplinary approach is essential for the management of such patients. Platinum-based chemotherapy currently represents the standard of care for EP-NECs of any site, mirroring the management of small-cell lung cancer (SCLC), but further approaches are still under investigation. Indeed, ongoing trials evaluating targeted therapies, immune checkpoint inhibitors (ICIs), and radionuclide therapy could provide potentially breakthrough therapeutic options. Given the relative dearth of evidence-based literature on these orphan diseases, the aim of this review is to provide an overview of the pathology and current treatment options, as well as to shed light on the most pressing unmet needs in the field.

9 June 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
BMBrigida Anna Maiorano
Brigida Anna Maiorano
GSGiovanni Schinzari
Giovanni Schinzari
DCDavide Ciardiello
Davide Ciardiello
Maria Grazia RodriquenzMaria Grazia Rodriquenz
Maria Grazia Rodriquenz
ACAntonio Cisternino
Antonio Cisternino
EMEvaristo Maiello
Evaristo Maiello
Background: In the last years, many new treatment options have widened the therapeutic scenario of genitourinary malignancies. Immunotherapy has shown efficacy, especially in the urothelial and renal cell carcinomas, with no particular relevance in prostate cancer. However, despite the use of immune checkpoint inhibitors, there is still high morbidity and mortality among these neoplasms. Cancer vaccines represent another way to activate the immune system. We sought to summarize the most recent advances in vaccine therapy for genitourinary malignancies with this review. Methods: We searched PubMed, Embase and Cochrane Database for clinical trials conducted in the last ten years, focusing on cancer vaccines in the prostate, urothelial and renal cancer. Results: Various therapeutic vaccines, including DNA-based, RNA-based, peptide-based, dendritic cells, viral vectors and modified tumor cells, have been demonstrated to induce specific immune responses in a variable percentage of patients. However, these responses rarely corresponded to significant survival improvements. Conclusions: Further preclinical and clinical studies will improve the knowledge about cancer vaccines in genitourinary malignancies to optimize dosage, select targets with a driver role for tumor development and growth, and finally overcome resistance mechanisms. Combination strategies represent possibly more effective and long-lasting treatments.

Verified
Journal Article
Open access
PDF file
DCDavide Ciardiello
Davide Ciardiello
BMBrigida Anna Maiorano
Brigida Anna Maiorano
Paola ParentePaola Parente
Paola Parente
Maria Grazia RodriquenzMaria Grazia Rodriquenz
Maria Grazia Rodriquenz
TLTiziana Pia Latiano
Tiziana Pia Latiano
EMEvaristo Maiello
Evaristo Maiello
Biliary tract cancers (BTC) represent a heterogeneous and aggressive group of tumors with dismal prognosis. For a long time, BTC has been considered an orphan disease with very limited therapeutic options. In recent years a better understanding of the complex molecular landscape of biology is rapidly changing the therapeutic armamentarium. However, while 40–50% of patients there are molecular drivers susceptible to target therapy, for the remaining population new therapeutic options represent an unsatisfied clinical need. The role of immunotherapy in the continuum of treatment of patients with BTC is still debated. Despite initial signs of antitumor-activity, single-agent immune checkpoint inhibitors (ICIs) demonstrated limited efficacy in an unselected population. Therefore, identifying the best partner to combine ICIs and predictive biomarkers represents a key challenge to optimize the efficacy of immunotherapy. This review provides a critical analysis of completed trials, with an eye on future perspectives and possible biomarkers of response.

23 March 2022 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
Maria Grazia RodriquenzMaria Grazia Rodriquenz
Maria Grazia Rodriquenz
DCDavide Ciardiello
Davide Ciardiello
TLTiziana Pia Latiano
Tiziana Pia Latiano
BMBrigida Anna Maiorano
Brigida Anna Maiorano
EMErika Martinelli
Erika Martinelli
EMEvaristo Maiello
Evaristo Maiello